The mixed Phase 2 results create binary risk: if a Phase 3 trial confirms subgroup efficacy, bezisterim could become the first approved Long COVID therapy, targeting a large unmet market. However, the failure to hit any endpoint in the ITT population and the exploratory nature of subgroup analyses mean the FDA may require additional studies. Monitor for details on Phase 3 design, endpoint selection, and any partnership or financing announcements given the company's $17M market cap.
Price Chart
Executive Summary
BioVie announced topline Phase 2 ADDRESS-LC trial results for bezisterim in Long COVID. The study failed to achieve statistical significance on any endpoint in the overall 203-patient intent-to-treat population, but showed statistically significant improvements in pre-specified subgroups with high baseline symptom burden. The company plans to advance to a Phase 3 trial, but the exploratory nature of the subgroup findings and the lack of an FDA-approved endpoint for Long COVID create substantial regulatory and clinical risk.
Key Facts
- Phase 2 ADDRESS-LC trial (N=203) did not achieve statistical significance on any endpoint in the overall ITT population.
- Statistically significant improvements were observed in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post-exertional malaise (approx. 78% of participants).
- 21 of 22 individual endpoints showed numerical trends favoring bezisterim over placebo in the overall population.
- Bezisterim's safety profile was similar to placebo; 41.6% of bezisterim patients had TEAEs vs. 55.9% for placebo.
- An estimated 17-20 million U.S. adults have Long COVID with no FDA-approved treatment options.
- The trial was fully funded by a $13.13 million grant from the U.S. Department of War.
- Company plans to advance to a confirmatory Phase 3 trial.
Financial Impact
No revenue or financial data disclosed. The trial was fully funded by a $13.13M DoW grant. No immediate financial impact from the results.
Risk Factors
- Phase 3 trial may fail to replicate subgroup findings in a prospective study.
- FDA has not validated any Long COVID endpoints as surrogate endpoints for approval.
- Company has a $17M market cap and may need to raise capital to fund Phase 3.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3361943 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $1.37 | awaiting T+20 | — | $1.33 (−2.92%) |
Sep 15, 2026 5w ago | Press Release | $1.75 $1.20 | ▼ −31.43% | ▼ −34.41% | $1.33 (−24.00%) |
Aug 14, 2026 10w ago | S-1/A | $1.17 $1.75 | ▼ −49.57% | ▼ −51.55% | $1.33 (−13.68%) |
Aug 6, 2026 11w ago | S-1/A | $1.35 $2.03 | ▼ −50.37% | ▼ −49.77% | $1.33 (+1.48%) |
Aug 6, 2026 11w ago | 8-K | $1.35 $2.03 | ▲ +50.37% | ▲ +49.77% | $1.33 (−1.48%) |
Jul 31, 2026 12w ago | S-1/A | $1.62 $2.28 | ▼ −40.74% | ▼ −39.50% | $1.33 (+17.90%) |
Jun 30, 2026 16w ago | EFFECT | $1.94 $1.37 | ▲ +29.38% | ▲ +28.35% | $1.33 (+31.44%) |
Apr 27, 2026 26w ago | Press Release | $1.59 $1.44 | ▼ −9.43% | ▼ −14.39% | $1.33 (−16.35%) |
Apr 14, 2026 27w ago | Press Release | $1.46 $1.35 | ▼ −7.53% | ▼ −13.83% | $1.33 (−8.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers